Antiandrogen Therapy and SBRT in Treating Patients With Recurrent Metastatic Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Jul 1, 2022
  • participants needed
    28
  • sponsor
    Jonsson Comprehensive Cancer Center
Updated on 25 January 2021
platelet count
prostatectomy
testosterone
metastasis
tumor cells
antiandrogen therapy
antiandrogens
abiraterone
metastatic prostate cancer
leuprolide
adenocarcinoma
prostate adenocarcinoma

Summary

This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in chemotherapy, such as leuprolide, apalutamide, and abiraterone acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving antiandrogen therapy and SBRT may work better in treating patients with prostate cancer.

Description

PRIMARY OBJECTIVES:

I. To assess the efficacy of combined systemic and tumor directed therapy for recurrent oligometastatic M1a,b prostate cancer patients with 1-5 metastases (exclusive of pelvic nodal N1 metastases) staged by prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-computed tomography (CT).

SECONDARY OBJECTIVES:

I. Time to biochemical progression. II. Time to additional antineoplastic therapy. III. Prostate cancer specific survival. IV. Safety and tolerability. V. Assessment of health related quality of life using the Functional Assessment of Cancer Therapy - Prostate (FACT-P) scale.

CORRELATIVE OBJECTIVES:

I. To determine genomic and transcriptomic features present in metastatic tumors in patients that respond to this multimodal therapy.

II. To evaluate biomarkers of response using circulating tumor cells (CTCs). III. To evaluate biomarkers of response using circulating tumor deoxyribonucleic acid (DNA) (ctDNA).

IV. To evaluate immunophenotypes of circulating immune cells.

OUTLINE

Patients receive a single dose of leuprolide subcutaneously (SC) on day 1 and apalutamide orally (PO) once daily (QD) and abiraterone acetate PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning 2 months of initiation of antiandrogen therapy (ADT), patients also receive SBRT over 1, 3, or 5 fractions in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up within 2 -4 weeks, every 30 days for 6 months, and then every 3 months thereafter.

Details
Condition Recurrent Prostate Carcinoma, Recurrent Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Stage IVB Prostate Cancer AJCC v8, Metastatic Prostate Adenocarcinoma, adenocarcinoma of the prostate metastatic
Treatment questionnaire administration, quality-of-life assessment, Leuprolide Acetate, stereotactic body radiation therapy, abiraterone acetate, Apalutamide
Clinical Study IdentifierNCT03902951
SponsorJonsson Comprehensive Cancer Center
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you male?
Do you have any of these conditions: Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation or Stage IVB Prostate Cancer AJCC v8 or Recurrent Prostate Carcinoma or Metastatic P...?
Do you have any of these conditions: adenocarcinoma of the prostate metastatic or Recurrent Prostate Carcinoma or Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation or Recu...?
Confirmed diagnosis of prostate adenocarcinoma after radical prostatectomy (primary small cell carcinoma of the prostate is not allowed, however adenocarcinoma with neuroendocrine differentiation is allowed)
Presence of 1-5 visible metastases (by PSMA PET-CT)
At least one metastasis must be M1a-b
Visceral metastases are not allowed
Patients may have any number of pelvic nodal metastases (but largest must be < 2 cm)
Metastases must be amenable to treatment with SBRT
Biopsy of one metastasis must be attempted, unless unsafe to perform
Patient must be fit to undergo SBRT to all visible sites of metastases, ADT
Total testosterone > 150 ng/dL prior to ADT (optimal time to measure total testosterone is between 8 and 9 am)
Adequate performance status (Eastern Cooperative Oncology Group [ECOG] 0-1)
Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization
Serum albumin >= 3.0 g/dL
Glomerular filtration rate (GFR) >= 45 mL/min
Serum potassium >= 3.5 mmol/L
Serum total bilirubin =< 1.5 x upper limits of normal (ULN)
Note: In subjects with Gilbert?s syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN
Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry

Exclusion Criteria

Any evidence of spinal cord compression (radiological or clinical)
Prior pelvic malignancy
Prior pelvic radiation aside from salvage prostate radiation
Concurrent malignancy aside from superficial skin cancers or superficial bladder tumors
Inability to undergo radiotherapy, or ADT
Primary small cell carcinoma of the prostate (prostate adenocarcinoma with neuroendocrine differentiation is allowed)
Inflammatory bowel disease or active collagen vascular disease
History of any of the following
Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)
Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization
Current evidence of any of the following
Uncontrolled hypertension
Gastrointestinal disorder affecting absorption
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/prednisolone once daily
Any condition that in the opinion of the investigator would preclude participation in this study
Concomitant strong CYP3A4 inducers. (If a strong CYP3A4 inducer must be co-administered, abiraterone acetate dose frequency will be adjusted). [SAFETY: Warning against use with CYP2C8 inhibitors with narrow therapeutic index is also pertinent to be included as it is also part of United States Prescribing Information (USPI): In a CYP2C8 drug-drug interaction trial in healthy subjects, the area under curve (AUC) of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA]
Treatment with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, a dose reduction of the CYP2D6 substrate may be considered
Baseline moderate and severe hepatic impairment (ChildPugh Class B & C)
Presence of visceral metastases (i.e., stage M1c)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note